# EASD KEYWORDS 2025

# **GROUP 1: Diabetes genetics, biomarkers and epidemiology**

01 Monogenic forms of diabetes

- 02 Genetics of type 1 diabetes
- 03 Genetics of type 2 diabetes
- 04 Diabetes epigenetics
- 05 Prediction of type 2 diabetes
- 06 Prevention of type 2 diabetes
- 07 Diabetes epidemiology
- 08 Risk of diabetes in immigrant populations

### **GROUP 2: Clinical and preclinical pancreas immunology and islet function**

09 Environmental factors (viruses, nutrients, toxins) of type 1 diabetes

- 10 Prediction and prevention of type 1 diabetes
- 11 Islet stem cells and beta cell generation
- 12 Transcriptional regulation and protein synthesis in the pancreas
- 13 Regulation of islet hormone secretion and exocytosis
- 14 Beta cell signal transduction
- 15 Beta cell damage, degeneration and apoptosis
- 16 Experimental immunology and animal models of type 1 diabetes
- 17 Clinical immunology
- 18 Pancreas and islet transplantation

# **GROUP 3: Peripheral hormone action in health and disease**

- 19 Insulin action, sensitivity and resistance
- 20 Insulin secretion in vivo
- 21 Environmental factors (viruses, nutrients, toxins) of insulin resistance
- 22 Peripheral non-insulin hormones
- 23 Omics in muscle
- 24 Carbohydrate metabolism
- 25 Protein metabolism
- 26 Exercise physiology
- 27 Metabolic dysfunction-associated fatty liver disease (MAFLD)
- 28 Diabetes in childhood

#### **GROUP 4: Diabetes mechanisms in obesity and more**

- 29 Adipocyte biology and fat cell models
- 30 Animal models of obesity and type 2 diabetes
- 31 Lipid metabolism in vivo
- 32 Adipose tissue function and hormones
- 33 Inflammation in obesity and type 2 diabetes
- 34 Omics in obesity or adipose tissue
- 35 Human weight regulation and obesity
- 36 Central nervous function in relation to obesity and type 2 diabetes
- 37 Senescence and obesity/diabetes

# **GROUP 5: Non-insulin based diabetes therapies**

38 Nutrition and diet
39 Oral therapies: metformin, sensitizers and other non-secretagogues
40 SGLT inhibitors
41 Incretin-based therapies
42 Novel agents

# **GROUP 6: Diabetes technology**

43 Insulin therapy
44 Glucose monitoring devices
45 Insulin pumps, connected pens and other devices
46 Hypoglycaemia
47 Health care delivery
48 Education
49 Digital diabetes health

# **GROUP 7: Microvascular complication of diabetes and beyond**

50 Diabetes and pregnancy
51 Neuropathy: somatic
52 Neuropathy: autonomic, incl. erectile dysfunction
53 Diabetic foot and skin disorders
54 Retinopathy
55 Nephropathy

56 Hypertension

#### **GROUP 8: Macrovascular complications of diabetes and beyond**

57 Cardiac complications

# 58 Macrovascular disease

- 59 Pathogenic mechanisms/ complications
- 60 Dyslipidaemia, lipoproteins
- 61 Endothelium

62 Cancer

63 Cognitive dysfunction and Alzheimer Disease

64 Diabetes and Mental Health

65 Socio-economic aspects of diabetes and complications

66 Other complications